Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Professor Irene Roberts appointed NIHR Theme Lead

Professor Irene Roberts, Professor of Paediatric Haematology at the University of Oxford Department of Paediatrics, has been appointed as Theme Lead for Non-Malignant Haematological Disorders for the National Institute of Health Research Rare Diseases Translational Research Collaboration.

This initiative, which runs from 2013 - 2017, aims to advance the understanding and management of rare diseases through integrating detailed documentation of their clinical features ('deep phenotyping') with molecular and functional studies, with the ultimate objective of improving their management.

Read more about the NIHR Rare Diseases Translational Research Collaboration here.

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.

World's first Phase II Nipah virus vaccine trial launch

Global Consortium Launched to Develop Next-Generation Malaria Vaccine

First Volunteer Receives Lassa Fever Vaccine in Cutting-edge Oxford Trial

Oxford-led study shows vaccine protection against Salmonella Paratyphi A

Oxford Cancer Announces 2025 CRIS Cancer Clinical Career Fellows